Hjem › Akut bifenoypisk leukemi › South Carolina › Greenville
Kliniske studier for Akut bifenoypisk leukemi i Greenville, SC
3 studier for Akut bifenoypisk leukemi søker deltakere på steder i og rundt Greenville (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekruttererFase 2
- BI-LO Charities Children's Cancer Center, Greenville
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruttererFase 3
- BI-LO Charities Children's Cancer Center, Greenville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruttererFase 1/2
- BI-LO Charities Children's Cancer Center, Greenville
Akut bifenoypisk leukemi-studier i andre byer
- Seattle, WA15 studier
- Houston, TX11 studier
- New York City, NY10 studier
- Atlanta, GA9 studier
- Durham, NC8 studier
- Memphis, TN7 studier
- Chicago, IL7 studier
- Charlotte, NC6 studier
- Baldwin Park, CA6 studier
- Aurora, CO6 studier
- Dallas, TX6 studier
- Philadelphia, PA6 studier
Andre studier i Greenville
- Ikke-småcellet lungekreft15 studier
- Brystkreft12 studier
- Akut myelogen leukemi10 studier
- Kreft (alle typer)9 studier
- Fedme9 studier
- Lungekreft9 studier
- Overvekt8 studier
- Prostatakreft7 studier
- Kolorektal kreft7 studier
- Mavekreft6 studier
- Perifer arteriell sykdom5 studier
- Burkitts lymfom5 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.